Recombinant Human Platelet-Derived Growth Factor-BB and Beta-Tricalcium Phosphate (rhPDGF-BB/β-TCP): An Alternative to Autogenous Bone Graft

Abstract

In patients requiring hindfoot or ankle arthrodesis, treatment with rhPDGF-BB/β-TCP resulted in comparable fusion rates, less pain, and fewer side effects as compared with treatment with autograft.

A Retrospective Clinical Comparison of Two Allogeneic Bone Matrices Containing Viable Osteogenic Cells in Patients Undergoing Foot and/or Ankle Arthrodesis

“…In a previous publication, the fusion rate using CBA after foot and/or ankle arthrodesis was higher than or comparable to historical autograft fusion rates [18]. For autograft, the per subject fusion rates were 66.4% (91/137) and 75.2% (103/137) at 6 and 12 months, respectively [2]. In comparison, for subjects who received CBA in the current study, the per subject fusion rates were 79.4% (54/68) and 93.3% (70/75) at 6 and 12 months, respectively indicating that use of CBA may result in increased fusion rates compared to autograft.…”

“…Successful individual joint fusion required the presence of greater than 50% bridging bone across the joint in at least one of the views as previously defined in an FDA regulated clinical study of foot and ankle arthrodesis [2]. Successful overall fusion for the subject required that each joint be fused.…”

“…An aging population and contributory comorbidities have led to a dramatic increase in foot and ankle arthrodeses from 1990 to 2007 [1] and the trend is expected to continue [2]. Foot and ankle arthrodesis is routinely utilized to decrease pain and reverse the disability associated with arthritis, trauma, instability, diabetes and malalignment [3][4][5].…”

Bone healing in 2016

“…PDGF is typically delivered to the fracture site in one of two forms: a platelet gel consisting of platelet-rich plasma mixed with thrombin, or recombinant human PDGF-BB with a beta-tricalcium phosphate scaffold. In a recent prospective RCT of 434 patients undergoing either hindfoot or ankle arthrodesis, the Authors compared the use of PDGF-BB with a beta-tricalcium phosphate scaffold to autograft in promoting fusion (40). The Authors found that compared to autograft, the use of PDGF-BB with a beta-tricalcium phosphate scaffold resulted in comparable fusion rates, less pain, and fewer side effects (40).…”

Kırık iyileşmesi

“…[18] Kırık iyileşmesinde trikalsiyon fosfat ile birlikte hazırlanmış PDGF uygulamaları konusunda yapılan çalışmalar vardır. [19] • İnflamatuvar evre • Damarlanma osteoblast çoğalması ve farklılaşmasını uyarır. [20] • BMP ile birlikte VEGF uygulamaları üzerine çalışmalarda olumlu sonuçlar elde edilmiştir.…”